PubMed · 8397265
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
1993. IDSA-Roerig HIV/AIDS training programs.. https://pubmed.ncbi.nlm.nih.gov/8397265/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Recently, two clinical trials demonstrated an antitumour effect of systemic high-dose beta-hCG therapy and of different regimens of local beta-hCG injections in AIDS-related Kaposi's sarcoma. We report the efficacy and safety of subcutaneous beta-hCG treatment (low-dose (2500-25000 IU/day) or high dose (25000-100000 IU/day)) in eight patients with advanced HIV disease in whom systemic chemotherapy and radiation were contraindicated or had failed. During therapy, serum hCG-concentrations as well as LH and FSH were measured. In the low-dose regimen one partial response was achieved. In the high-dose regimen, one patient maintained his response without further improvement. Three patients had stable disease and four patients disease progression. Serious side effects related to beta-hCG therapy were not observed. In conclusion, systemic beta-hCG-therapy for Kaposi's sarcoma is safe but associated with regression only in a minority of patients with advanced HIV-disease.
Explore the source record for details and available documents.
All blood donations in the United States are screened for human immunodeficiency virus (HIV), the virus that causes AIDS; in spite of this, potentially infectious donations are still made by donors who are infectious but have not yet developed detectable HIV antibodies. A steady-state model for blood donations is used to calculate the expected number of potentially infectious blood donations made by repeat blood donors in a specified time interval. The expected number of potentially infectious donations made by each infectious blood donor who subsequently becomes HIV positive is calculated, and estimators of this quantity are presented. The relative risks due to donations from repeat and first-time donors is discussed. Estimates of the proportion of all blood donations made at 19 American Red Cross regional blood centers that are potentially infectious are presented.